FDA decides to review information on Avastin for advanced HER2-negative breast cancer

[News]

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

More... (http://www.news-medical.net/news/20100918/FDA-decides-to-review-information-on-Avastin-for-advanced-HER2-negative-breast-cancer.aspx)